Phase 2, open-label RCT: Stereotactic body radiotherapy plus pembrolizumab and trametinib vs. stereotactic body radiotherapy plus gemcitabine for locally recurrent pancreatic cancer after surgical resection.

Stereotactic body radiotherapy plus pembrolizumab and trametinib versus stereotactic body radiotherapy plus gemcitabine for locally recurrent pancreatic cancer after surgical resection: an open-label, randomised, controlled, phase 2 trial – The Lancet Oncology (link to abstract – $ for full-text)